NCT00702494已完成1 期
An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 4
- 主要终点
- Safety and tolerability of an anti-PlGF antibody
研究概览
简要总结
TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented.
In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed malignity
- •Measurable disease
- •Performance status 1 or less (ECOG)
排除标准
- •Acute illness or infection
- •Concurrent second malignancy
结局指标
主要结局
Safety and tolerability of an anti-PlGF antibody
时间窗: 85 days
次要结局
- Determine multiple dose IV pharmacokinetics(85 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.Osteoarthritis, HipOsteoarthritis, KneeNCT02709486Pfizer849
已完成
1 期
A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male VolunteersHealthyNCT00612196ThromboGenics56
终止
1 期
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)Osteogenesis ImperfectaNCT05231668Sanofi16
已完成
1 期
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory MedulloblastomaRelapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)NCT02748135Oncurious NV18
已完成
1 期
TMB-365 and TMB-380 in Suppressed HIV-1 Infected IndividualsHIV-1-infectionNCT05275998TaiMed Biologics Inc.51